Clinical Trial Update: Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 trial is evaluating the combination of copanlisib and nivolumab in patients with Richter's transformation or transformed indolent non-Hodgkin lymphoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Indolent Non-hodgkin Lymphoma
• Lymphoplasmacytic Lymphoma
• Marginal Zone Lymphoma
• Richter Syndrome

Drugs mentioned

• Aliqopa (copanlisib)
• OPDIVO (nivolumab)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING